Nine weeks of the right immunotherapy before surgery looks like it can erase the usual fear of a colon cancer comeback—at least for a specific, testable group of patients.
Quick Take
- A UK trial (NEOPRISM-CRC) followed 32 stage 2/3 patients with dMMR/MSI-high colorectal cancer who received pembrolizumab before surgery.
- After a median of 33 months, every patient remained cancer-free, and 59% had no detectable cancer in the removed tissue.
- The approach aims to replace the old rhythm of surgery first and chemotherapy after, which still sees meaningful relapse rates.
- ctDNA “liquid biopsy” monitoring helped track response and may become the practical referee for who needs more treatment.
NEOPRISM-CRC: A Small Trial With an Outsized Message
UCL and UCLH investigators enrolled 32 patients across five UK hospitals with stage 2/3 colorectal cancer carrying a telltale biology: mismatch repair deficiency, also called dMMR or MSI-high. Patients received a short, nine-week course of pembrolizumab before surgery, then skipped the usual postoperative chemotherapy. Follow-up presented at AACR 2026 showed a striking headline: no recurrences at 33 months, with 59% reaching a pathological complete response.
Numbers like “32 patients” always demand humility, but the clinical signal matters because it targets the stubborn problem of relapse. Standard care can cure many people, yet a meaningful share still sees the cancer return after surgery and chemotherapy. NEOPRISM-CRC flips the timeline: treat the immune system while the tumor is still present, then operate. That sequencing matters, because the tumor provides the immune system a “wanted poster” of what to attack.
Why dMMR/MSI-High Tumors Act Like Immunotherapy Magnets
dMMR/MSI-high cancers carry errors in DNA repair machinery, which leaves the tumor packed with mutations. More mutations mean more abnormal proteins that immune cells can recognize. That biological reality explains why pembrolizumab earned broad attention years ago in advanced MSI-high cancers and why researchers pushed it earlier into potentially curative disease. The practical takeaway for patients is simple: this strategy only makes sense if the tumor’s genetics say it should.
If the “miracle” depends on a subtype, then universal access to accurate MSI/MMR testing becomes the real gatekeeper. Many health systems talk big about equity while underfunding basic diagnostics. A results-first approach would prioritize the cheapest, highest-value step: test correctly up front, then reserve expensive drugs for the patients most likely to benefit, instead of guessing after the fact.
ctDNA: The Quiet Tool That Could Keep Overtreatment in Check
The trial also leaned on circulating tumor DNA, a blood test that looks for fragments of tumor genetic material. When ctDNA clears, it suggests the body has little to no measurable residual disease. That matters because the biggest risk in early-stage colon cancer is invisible leftovers, not the tumor surgeons can see. A tool that tracks “leftover risk” in real time could prevent the reflex to treat everyone aggressively “just in case,” which is how people end up paying for toxicity they never needed.
For readers who’ve watched friends endure chemotherapy neuropathy or exhaustion that lingers for years, the point lands hard: avoiding unnecessary chemo is not a lifestyle perk; it’s long-term function. A nine-week pre-surgery immunotherapy course also compresses the chaos of treatment into a clearer window. People can plan, work, and take care of family around a defined schedule. That’s not a soft benefit—predictability is a form of quality of life that medicine often undervalues.
The Catch: What This Result Does Not Prove Yet
NEOPRISM-CRC is not a randomized, head-to-head trial against standard treatment, and it doesn’t yet answer how this holds up at five years and beyond. A clean 33-month record is powerful, but oncology is littered with early wins that faded with longer follow-up or broader use. The right posture is confident curiosity, not blind celebration: expand the study, confirm durability, and define exactly which patients can safely skip postoperative chemotherapy.
Cost also refuses to stay offstage. Pembrolizumab is not cheap, and any expansion of use will trigger the familiar fight between patient access, payer budgets, and drug-company incentives. The only sustainable way through is precision: use immunotherapy where biology predicts dramatic benefit, and use ctDNA and pathology to avoid stacking additional therapies out of habit. That’s the kind of disciplined decision-making taxpayers and families can support without feeling played.
What This Could Mean for the Next 40-Year-Old Diagnosed
Colorectal cancer has been rising in younger adults, while many older adults still face the traditional gauntlet of surgery plus months of chemotherapy. The most realistic near-term change is not that “colon cancer is solved,” but that treatment becomes more tailored. dMMR/MSI-high patients may get a shorter, front-loaded immunotherapy plan and less chemo afterward, while everyone else continues on different tracks until their own breakthroughs arrive.
Colon cancer breakthrough keeps patients cancer-free for nearly 3 years https://t.co/zUb4YkASJ1
— Un1v3rs0 Z3r0 (@Un1v3rs0Z3r0) May 6, 2026
The simplest action item is the least glamorous: ask whether the tumor has been tested for MMR/MSI status and, when available, how ctDNA might guide follow-up. NEOPRISM-CRC’s real disruption is not a new miracle drug—it’s a new discipline. Match therapy to tumor genetics, measure response with modern tools, and stop punishing patients with extra treatment when the evidence says they’re already winning.
Sources:
Breakthrough Bowel Cancer Trial Leaves Patients Cancer-Free for Nearly 3 Years
Patients remain cancer-free nearly 3 years after receiving experimental immunotherapy
Rectal Cancer Disappears After Experimental Use of Immunotherapy
Breakthrough Bowel Cancer Trial Leaves Patients Cancer-Free for Nearly 3 Years
